PortfoliosLab logoPortfoliosLab logo
RxSight, Inc. (RXST)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US78349D1072
CUSIP
78349D107
IPO Date
Jul 30, 2021

Highlights

Market Cap
$253.64M
Enterprise Value
$245.90M
EPS (TTM)
-$0.95
Total Revenue (TTM)
$134.48M
Gross Profit (TTM)
$103.01M
EBITDA (TTM)
-$38.63M
Year Range
$5.90 - $17.52
Target Price
$10.33
ROA (TTM)
-12.49%
ROE (TTM)
-14.13%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in RxSight, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

RxSight, Inc. (RXST) has returned -40.88% so far this year and -75.60% over the past 12 months.


RxSight, Inc.

1D
1.15%
1M
-17.65%
YTD
-40.88%
6M
-31.48%
1Y
-75.60%
3Y*
-28.25%
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Jul 30, 2021, RXST's average daily return is +0.02%, while the average monthly return is -0.18%.

Historically, 45% of months were positive and 55% were negative. The best month was Nov 2023 with a return of +36.2%, while the worst month was Apr 2025 at -41.7%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, RXST closed higher 50% of trading days. The best single day was Jan 10, 2022 with a return of +28.2%, while the worst single day was Apr 3, 2025 at -37.9%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-16.60%-13.92%-17.65%-40.88%
2025-1.48%-16.27%-10.97%-41.70%3.87%-14.98%-40.15%16.20%-0.55%-2.22%29.92%-8.76%-69.69%
202412.87%19.91%-5.48%1.07%12.16%2.91%-23.93%23.20%-12.34%2.49%-7.46%-26.66%-14.73%
202310.50%-2.00%21.57%7.31%36.15%18.18%15.87%-13.07%-3.86%-20.62%36.22%33.69%218.23%
2022-8.53%30.42%-7.75%-0.89%11.33%3.07%6.25%-16.38%-4.08%3.67%2.65%-0.78%12.62%
2021-3.87%-17.62%-5.45%-9.43%3.69%-29.69%

Benchmark Metrics

RxSight, Inc. has an annualized alpha of -8.19%, beta of 1.27, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since August 02, 2021.

  • This stock participated in 190.48% of S&P 500 Index downside but only 108.58% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-8.19%
Beta
1.27
0.10
Upside Capture
108.58%
Downside Capture
190.48%

Return for Risk

Risk / Return Rank

RXST ranks 6 for risk / return — in the bottom 6% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.


RXST Risk / Return Rank: 66
Overall Rank
RXST Sharpe Ratio Rank: 66
Sharpe Ratio Rank
RXST Sortino Ratio Rank: 66
Sortino Ratio Rank
RXST Omega Ratio Rank: 44
Omega Ratio Rank
RXST Calmar Ratio Rank: 11
Calmar Ratio Rank
RXST Martin Ratio Rank: 1515
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for RxSight, Inc. (RXST) and compare them to a chosen benchmark (S&P 500 Index).


RXSTBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.91

0.90

-1.80

Sortino ratio

Return per unit of downside risk

-1.47

1.39

-2.85

Omega ratio

Gain probability vs. loss probability

0.78

1.21

-0.43

Calmar ratio

Return relative to maximum drawdown

-1.00

1.40

-2.40

Martin ratio

Return relative to average drawdown

-1.26

6.61

-7.87

Explore RXST risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


RxSight, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the RxSight, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the RxSight, Inc. was 90.53%, occurring on Mar 30, 2026. The portfolio has not yet recovered.

The current RxSight, Inc. drawdown is 90.42%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-90.53%May 16, 2024468Mar 30, 2026
-48.21%Aug 3, 2021111Jan 7, 2022316Apr 13, 2023427
-37.34%Aug 1, 202364Oct 30, 202326Dec 6, 202390
-20.23%Feb 28, 202412Mar 14, 202434May 2, 202446
-13.18%Dec 28, 20234Jan 3, 20243Jan 8, 20247

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of RxSight, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how RxSight, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for RXST relative to other companies in the Medical Devices industry. Currently, RXST has a P/S ratio of 1.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for RXST in comparison with other companies in the Medical Devices industry. Currently, RXST has a P/B value of 0.9. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items